Corporate Snapshot

MultiCell Technologies, Inc. ("MultiCell" or "the Company") is an integrated biopharmaceutical company that uses proprietary immune system modulation technologies to discover and commercialize new therapeutics. The Company's expertise in Toll-like receptor (TLR) and T-Cell tolerance technologies has lead to the discovery of new therapeutics for the treatment of degenerative neurological disease such as multiple sclerosis (MS); metabolic and endocrinological disorders such as Type 1 diabetes, hepatitis, and sepsis; degenerative ocular disorders such as macular degeneration; and infectious disease such as influenza A. MultiCell's therapeutic pipeline includes MCT-125, directed at fatigue in MS; MCT-175, targeting relapse-remitting MS (RR-MS); MCT-275, targeting treatment of Type 1 diabetes; MCT-355, directed at macular degeneration; and MCT-465, addressing influenza A. MultiCell also specializes in developing primary cell immortalization technologies to produce cell-based assay systems for use in drug discovery. The Company has partnered this technology with large capitalization pharmaceutical companies, including Pfizer, Inc. (PFE-NYSE), Bristol-Myers Squibb Co. (BMY-NYSE), and Eisai Co., Ltd. to evaluate drug candidates for cytochrome P450 induction and toxicity.

* The Corporate Snapshot was last updated on July 31, 2006.

Latest Research

Quarterly
Update

2006-07-31

Click to View

Stock Information (MCET.OB)